MX2021011351A - Tecnologias utiles para la preparacion de oligonucleotidos. - Google Patents

Tecnologias utiles para la preparacion de oligonucleotidos.

Info

Publication number
MX2021011351A
MX2021011351A MX2021011351A MX2021011351A MX2021011351A MX 2021011351 A MX2021011351 A MX 2021011351A MX 2021011351 A MX2021011351 A MX 2021011351A MX 2021011351 A MX2021011351 A MX 2021011351A MX 2021011351 A MX2021011351 A MX 2021011351A
Authority
MX
Mexico
Prior art keywords
oligonucleotide preparation
technologies
technologies useful
preparation
useful
Prior art date
Application number
MX2021011351A
Other languages
English (en)
Inventor
Chandra Vargeese
David Charles Donnell Butler
Sethumadhavan Divakaramenon
Pachamuthu Kandasamy
Jayakanthan Kumarasamy
Gopal Reddy Bommineni
Mamoru Shimizu
Mohammed Rowshon Alam
Keith Andrew Bowman
Bijay Tilak Bhattarai
Stephany Michelle Standley
Original Assignee
Wave Life Sciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wave Life Sciences Ltd filed Critical Wave Life Sciences Ltd
Publication of MX2021011351A publication Critical patent/MX2021011351A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/02—Phosphorylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Entre otras cosas, la presente divulgación proporciona tecnologías para la preparación de oligonucleótidos, particularmente para la preparación de oligonucleótidos controlada quiralmente, proporcionando las tecnologías una pureza en bruto y un rendimiento enormemente mejorados, y reduciendo significativamente los costes de fabricación.
MX2021011351A 2019-03-20 2020-03-19 Tecnologias utiles para la preparacion de oligonucleotidos. MX2021011351A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962821423P 2019-03-20 2019-03-20
PCT/US2020/023735 WO2020191252A1 (en) 2019-03-20 2020-03-19 Technologies useful for oligonucleotide preparation

Publications (1)

Publication Number Publication Date
MX2021011351A true MX2021011351A (es) 2021-12-10

Family

ID=72520512

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021011351A MX2021011351A (es) 2019-03-20 2020-03-19 Tecnologias utiles para la preparacion de oligonucleotidos.

Country Status (12)

Country Link
US (1) US20230089442A1 (es)
EP (1) EP3941924A4 (es)
JP (1) JP2022525541A (es)
KR (1) KR20210149750A (es)
CN (1) CN113748116A (es)
AU (1) AU2020241559A1 (es)
BR (1) BR112021018492A2 (es)
CA (1) CA3134036A1 (es)
IL (1) IL286487A (es)
MX (1) MX2021011351A (es)
SG (1) SG11202110045PA (es)
WO (1) WO2020191252A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201500239VA (en) 2012-07-13 2015-03-30 Wave Life Sciences Japan Asymmetric auxiliary group
WO2014012081A2 (en) 2012-07-13 2014-01-16 Ontorii, Inc. Chiral control
RU2708237C2 (ru) 2014-08-22 2019-12-05 Общество с ограниченной ответственностью "НооГен" Модифицированные олигонуклеотиды и способ их получения
MA43072A (fr) 2015-07-22 2018-05-30 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
CN114685589A (zh) 2016-03-13 2022-07-01 波涛生命科学有限公司 用于亚磷酰胺和寡核苷酸合成的组合物和方法
WO2017220751A1 (en) 2016-06-22 2017-12-28 Proqr Therapeutics Ii B.V. Single-stranded rna-editing oligonucleotides
WO2018098264A1 (en) 2016-11-23 2018-05-31 Wave Life Sciences Ltd. Compositions and methods for phosphoramidite and oligonucleotide synthesis
JP7557941B2 (ja) 2017-06-02 2024-09-30 ウェイブ ライフ サイエンシズ リミテッド オリゴヌクレオチド組成物及びその使用方法
WO2018223056A1 (en) 2017-06-02 2018-12-06 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
EP3642182A4 (en) 2017-06-21 2020-12-09 Wave Life Sciences Ltd. COMPOUNDS, COMPOSITIONS AND SYNTHESIS METHODS
KR20200035301A (ko) 2017-08-08 2020-04-02 웨이브 라이프 사이언시스 리미티드 올리고뉴클레오티드 조성물 및 이의 방법
KR20200052369A (ko) 2017-09-18 2020-05-14 웨이브 라이프 사이언시스 리미티드 올리고뉴클레오티드 제조 기술
EP3694530A4 (en) 2017-10-12 2021-06-30 Wave Life Sciences Ltd. OLIGONUCLEOTIDE COMPOSITIONS AND METHOD FOR THEREFORE
MX2022000113A (es) * 2019-07-09 2022-02-10 Hoffmann La Roche Proceso para la desproteccion de oligonucleotidos.
WO2023152371A1 (en) 2022-02-14 2023-08-17 Proqr Therapeutics Ii B.V. Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia
WO2024013360A1 (en) 2022-07-15 2024-01-18 Proqr Therapeutics Ii B.V. Chemically modified oligonucleotides for adar-mediated rna editing
WO2024013361A1 (en) 2022-07-15 2024-01-18 Proqr Therapeutics Ii B.V. Oligonucleotides for adar-mediated rna editing and use thereof
GB202215614D0 (en) 2022-10-21 2022-12-07 Proqr Therapeutics Ii Bv Heteroduplex rna editing oligonucleotide complexes
WO2024110565A1 (en) 2022-11-24 2024-05-30 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis
GB202218090D0 (en) 2022-12-01 2023-01-18 Proqr Therapeutics Ii Bv Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency
WO2024121373A1 (en) 2022-12-09 2024-06-13 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of cardiovascular disease
GB202300865D0 (en) 2023-01-20 2023-03-08 Proqr Therapeutics Ii Bv Delivery of oligonucleotides
WO2024175550A1 (en) 2023-02-20 2024-08-29 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease
GB202304363D0 (en) 2023-03-24 2023-05-10 Proqr Therapeutics Ii Bv Chemically modified antisense oligonucleotides for use in RNA editing
WO2024206175A1 (en) 2023-03-24 2024-10-03 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of neurological disorders
WO2024200472A1 (en) 2023-03-27 2024-10-03 Proqr Therapeutics Ii B.V. Antisense oligonucleotides for the treatment of liver disease

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2498111A1 (en) * 2002-09-11 2004-03-25 Merck & Co., Inc. Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors
EP2620428B1 (en) * 2010-09-24 2019-05-22 Wave Life Sciences Ltd. Asymmetric auxiliary group
WO2014012081A2 (en) * 2012-07-13 2014-01-16 Ontorii, Inc. Chiral control
SG11201500239VA (en) * 2012-07-13 2015-03-30 Wave Life Sciences Japan Asymmetric auxiliary group
MA43072A (fr) * 2015-07-22 2018-05-30 Wave Life Sciences Ltd Compositions d'oligonucléotides et procédés associés
US11591362B2 (en) * 2017-03-29 2023-02-28 Roche Innovation Center Copenhagen A/S Orthogonal protecting groups for the preparation of stereodefined phosphorothioate oligonucleotides
AU2019252680A1 (en) * 2018-04-12 2020-10-22 Wave Life Sciences Ltd. Oligonucleotide compositions and methods of use thereof
EP3790596A4 (en) * 2018-05-11 2022-04-06 Wave Life Sciences Ltd. OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE
CN113383078A (zh) * 2018-12-06 2021-09-10 波涛生命科学有限公司 寡核苷酸组合物及其方法
CN114585737A (zh) * 2019-10-06 2022-06-03 波涛生命科学有限公司 寡核苷酸组合物及其使用方法

Also Published As

Publication number Publication date
SG11202110045PA (en) 2021-10-28
BR112021018492A2 (pt) 2021-11-23
CN113748116A (zh) 2021-12-03
EP3941924A1 (en) 2022-01-26
IL286487A (en) 2021-10-31
WO2020191252A1 (en) 2020-09-24
US20230089442A1 (en) 2023-03-23
JP2022525541A (ja) 2022-05-17
KR20210149750A (ko) 2021-12-09
EP3941924A4 (en) 2022-12-28
AU2020241559A1 (en) 2021-11-11
CA3134036A1 (en) 2020-09-24

Similar Documents

Publication Publication Date Title
MX2021011351A (es) Tecnologias utiles para la preparacion de oligonucleotidos.
EP4069281A4 (en) NOVEL ENZYMES
MX2019010769A (es) Proceso para la preparacion de enlazadores de farmacos de glucuronidos y compuestos intermediarios de los mismos.
PH12015501953A1 (en) Substituted nucleotide analogs
MX2018006148A (es) Inhibidores de cxcr2.
AU2018258581A8 (en) RAF-degrading conjugate compounds
MX2019011778A (es) Composicion para producir tagatosa y procedimiento de produccion de tagatosa usando la misma.
EP3562833A4 (en) ALGAE MUTANTS WITH HIGH PRODUCTIVITY AND REDUCED PHOTOSYNTHETIC ANTENNA
MX2019000664A (es) Preparacion de 14-metil-16-oxabiciclo[10.3.1]pentadecenos de 3-metil-1,5 ciclopentadecanediona.
MX2022000632A (es) Cauchos de dieno terminados en carboxi.
MX2019011758A (es) Composicion para producir tagatosa y procedimiento de produccion de tagatosa usando la misma.
MX2013013463A (es) Nuevo procedimiento para la síntesis de rifaximina y una nueva forma pseudocristalina de rifaximina obtenida con el mismo.
MY190551A (en) Method for preparing pyrrolo[3,2-d]pyrimidine compound, and intermediates thereof
MX2019008241A (es) Un enlazador polipeptídico para preparar anticuerpos multispecíficos.
EP3945848A4 (en) PROBIOTICS TO REDUCE METHANE PRODUCTION
EP3820991A4 (en) MODIFIED VARIANT PANTOTHENATE KINASE ENZYMES
EP3962643A4 (en) CATALYSTS FOR HYDROGEN PRODUCTION
MX2021011385A (es) Compuestos antineoplasicos.
WO2019224548A3 (en) Methods for the production of methacrylates
MX2017014890A (es) Metodos de produccion de acetolactato-descarboxilasa (aldc).
WO2017051437A3 (en) A nucleotide sequence encoding 7-dehydrocholesterol reductase, recombinant constructs and recombinant organisms comprising said sequence
EP3933044A4 (en) CONVENIENT ENZYME SYNTHESIS OF 3', 3'-CGAMP
EP4069835A4 (en) PROTHROMBIN PURIFICATION
MX2022006178A (es) Composiciones que comprenden tricianohexano.
MX2017012733A (es) Produccion de compuestos fragantes.